(Q42626935)
Statements
1 reference
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer (English)
1 reference
K Fizazi
1 reference
J S De Bono
1 reference
A Flechon
1 reference
A Heidenreich
1 reference
E Voog
1 reference
N B Davis
1 reference
Ming Qi
1 reference
R Bandekar
1 reference
J T Vermeulen
1 reference
M Cornfeld
1 reference
G R Hudes
1 reference
28 November 2011
1 reference
1 reference
Identifiers
1 reference